# Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT03327402** · PHASE1 · COMPLETED · sponsor: **Shire** · enrollment: 24 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** SHP465

## Key facts

- **NCT ID:** NCT03327402
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-13
- **Primary completion:** 2018-10-05
- **Final completion:** 2018-10-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03327402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03327402, "Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03327402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*